- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03011190
Effectiveness of the Iconic Therapy for Borderline Personality Disorder Symptoms
May 13, 2018 updated by: Silvia Elisa Hurtado Santiago
Effectiveness of the Iconic Therapy in Youth With Suicidal Ideation/Self-injuring Behavior and Borderline Personality Traits: Study Protocol for a Randomized Controlled Trial
Borderline personality disorder (BPD) is the most prevalent personality disorder in young community population whose most severe complication is suicide.
Pharmacotherapy should not be used as the primary treatment for BPD as the benefits are unclear.
Psychotherapy is the main treatment for people with BPD and the current recommendation is adapting available comprehensive treatments to develop easier and briefer therapies that are also effective.
Iconic Therapy is an innovative option whose good clinical results should be validated on a clinical trial.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Borderline Personality Disorder (BPD) in the early adulthood is an increasing diagnosis among general population.
First symptoms detection and early intervention might help prevent its aggravation and further BPD diagnosis.
Iconic Therapy is an innovative manual-driven psychotherapy to specifically and intensively treat BPD symptoms.
Preliminary clinical results are good.
The aim of the present study is to assess the effectiveness of the Iconic Therapy in comparison to a support structured therapy in an ecological setting (Spanish public specialized mental health care).
The study is planned as a randomized controlled prospective trial that will randomize 60 young people (15 to 25 years old) with suicidal ideation/self-injuring behaviour and borderline personality traits.
Participants will be randomly assigned to one of the two groups: Iconic Therapy or support structured therapy on a 1:1 basis.
Both the Iconic Therapy and the support therapy programs consist of 10-12 weekly sessions delivered by two trained psychologists for about 8-12 outpatients on group format.
The primary outcome measure is the change of symptoms severity assessed by the Borderline Personality Disorder List (BSL-23).
Secondary outcomes include suicidal ideation and behavior, non-suicidal self-injures maladjustment to the daily life and economic evaluation for health care.
Assessments will be performed at baseline after the intervention 6 and 12 months of follow-up.
It is hypothesized that those attending the Iconic Therapy group will show a permanently reduction of the severity of symptoms as compared with those attending the structured support group.
Data will be analyzed using generalized estimating equations (GEE) models.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Malaga, Spain, 29190
- Silvia E. Hurtado-Santiago
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 25 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 15-25 years old
- Suicidal ideation and/or self-injuring behavior
- BPD behavioural trends defined as the cut point for alarming BPD traits (>38 score) on Exploratory Questionnaire of Personality-III-BPD (CEPER-III-BPD)
- Sufficiently proficient in Spanish to follow the treatment
Exclusion Criteria:
- Antisocial personality disorder as measured in the Clinical Interview for Diagnostic and Statistical Manual (DSM-IV Axis II) (SCID-II)
- Substance or alcohol abuse
- High suicidal risk
- Negative expectations to be enrolled in the study as measured < 35 by the Expectation of Treatment Scale (ETS)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Iconic Therapy
The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions.
The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.
Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place.
They will depend on participant´s requirements.
They will consist on coaching their demands and providing human support throughout the study.
|
Educate people with difficulty in regulating their emotions and help them acquire skills to do so
|
|
Active Comparator: Support therapy
Support therapy consist of 10-12 weekly group sessions of 60-minute duration.
Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few.
The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place.
They will depend on participant´s requirements.
They will consist on coaching their demands and providing human support throughout the study.
|
Educate people with difficulty in regulating their emotions and help them acquire skills to do so
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on the severity of borderline personality disorder measured by Borderline Personality Symptom List (BSL-23).
Time Frame: Baseline and up to 12 months after inclusion.
|
This questionnaire (BSL-23) is a dimensional instrument: the most widely used to assess borderline personality disorder symptomatology improvement in clinical trials.
The Spanish validated version of the questionnaire will be used.
|
Baseline and up to 12 months after inclusion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sociodemographic variables
Time Frame: Baseline
|
The following socio-demographic data will be collected: gender, age, marital status, parents´nationality, coexistence (no studies, primary studies, Secondary studies, University, Professional formation), occupation (student, working, both studying and working, pensioner) and family member or allied friend´s phone number for further contacts.
|
Baseline
|
|
Change on the suicidal ideation and behavior measured by the Columbia Suicide History Form (SSRS).
Time Frame: Baseline and up to 12 months after inclusion.
|
this instrument measures ideation (wish, thinking, intention and plan), ideation severity (frequency, duration, control capacity, disuasory elements and reasons) and suicidal behavior (attempts and acts).
It is considered an adequate tool for treatment planning and research.
|
Baseline and up to 12 months after inclusion.
|
|
Change on non-suicidal self-injure diagnosis
Time Frame: Baseline and up to 12 months after inclusion.
|
It does not exist a specific validated scale to assess non suicidal self injures so the investigators collected and asked about all the 6 Diagnostic and Statistical Manual (DSM-V) criteria.
The investigators aim to separately describe the incidence of suicide attempts/acts vs non suicidal self injures in this study.
|
Baseline and up to 12 months after inclusion.
|
|
Change on the economic evaluation measured by the Client Service Receipt Inventory (CSRI) - adapted Spanish version (CSRI-Spanish version)
Time Frame: Baseline and up to 12 months after inclusion.
|
Questionnaire to assess use of healthcare/social care services and other economic impacts.
This instrument has two subscales to assess either direct costs (emergency services/hospital admissions use, specialised medical consultations, prescribed diagnosis trials and consumed medication) or indirect costs (absenteeism and quantity/quality of job performance on a 100-point scales).
|
Baseline and up to 12 months after inclusion.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on the maladjustment to the daily life measured by the Maladjustment Scale (EI).
Time Frame: Baseline and up to 12 months after inclusion.
|
It is a brief instrument of 6 self-report items assessing maladjustment to the daily life on psychiatric population.
A six point Likert scale ranging from 0 (not at all) to 5 (very strong) is used.
It is sensitive to therapeutic changes.
|
Baseline and up to 12 months after inclusion.
|
|
Satisfaction with the treatment assessed by the Opinion of treatment scale (OTS).
Time Frame: Through therapy completion, an average of 12 weeks.
|
It is a quick and easy to administer 6-item scale for assessing satisfaction and rationale credibility : how believable, convincing and logical the treatment was from 0 (not at all) to 10 (very strong).
|
Through therapy completion, an average of 12 weeks.
|
|
Change on the perceived subjective global improvement measured on a 7-point ad hoc Likert scale
Time Frame: Through therapy completion (an average of 12 weeks) and up to 12 months after inclusion
|
Participants will be asked about their subjective impression : much/quite/little bit better, the same or much/quite/little bit worse compared to when they entered the study.
|
Through therapy completion (an average of 12 weeks) and up to 12 months after inclusion
|
|
Change on family and friends´ perceived global improvement
Time Frame: Through therapy completion (an average of 12 weeks) and up to 12 months after inclusion
|
Family and friend´s perceived global improvement will be asked on a 7-point ad hoc Likert scale: much/quite/little bit better, the same or much/quite/little bit worse compared to when they entered the study.
|
Through therapy completion (an average of 12 weeks) and up to 12 months after inclusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Rosa Bersabé, Psychologist, Malaga University
- Study Director: Fermín Mayoral, Psychiatrist, Hospital Regional de Malaga
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongerslev MT, Mattivi JT, Jorgensen MS, Faltinsen E, Todorovac A, Sales CP, Callesen HE, Lieb K, Simonsen E. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020 May 4;5(5):CD012955. doi: 10.1002/14651858.CD012955.pub2.
- Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev. 2021 Apr 22;4(4):CD013668. doi: 10.1002/14651858.CD013668.pub2.
- Hurtado-Santiago S, Guzman-Parra J, Mayoral F, Bersabe RM. Iconic Therapy for the reduction of borderline personality disorder symptoms among suicidal youth: a preliminary study. BMC Psychiatry. 2022 Mar 29;22(1):224. doi: 10.1186/s12888-022-03862-x.
- Hurtado-Santiago S, Guzman-Parra J, Bersabe RM, Mayoral F. Effectiveness of iconic therapy for the reduction of borderline personality disorder symptoms among suicidal youth: study protocol for a randomised controlled trial. BMC Psychiatry. 2018 Sep 3;18(1):277. doi: 10.1186/s12888-018-1857-x.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2015
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
December 28, 2016
First Submitted That Met QC Criteria
January 3, 2017
First Posted (Estimate)
January 5, 2017
Study Record Updates
Last Update Posted (Actual)
May 15, 2018
Last Update Submitted That Met QC Criteria
May 13, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- shs-ico-2015-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Personality Disorder, Borderline
-
University of California, Los AngelesRecruitingBorderline Personality Disorder | Borderline Personality | BPD - Borderline Personality DisorderUnited States
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Waypoint Centre for Mental Health CareRecruitingBorderline Personality Disorder (BPD)Canada
-
Mclean HospitalNot yet recruitingBorderline Personality Disorder (BPD)United States
-
University Hospital, MontpellierNot yet recruitingBorderline Personality Disorder | Borderline Personality Disorder (BPD)
-
University Hospital, ToulouseNot yet recruitingBorderline Personality Disorder (BPD) | Infusion of Ketamine in Severe Borderline Personality DisorderFrance
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompletedBorderline Personality Disorder (BPD)Italy
Clinical Trials on Emotional regulation
-
Icahn School of Medicine at Mount SinaiCompletedTraumatic Brain Injury | Executive Dysfunction | Emotional DysregulationUnited States
-
Lorena Wenger AmengualAgencia Nacional de Investigación y DesarrolloCompletedEmotional RegulationChile
-
University Rovira i VirgiliActive, not recruitingEmotional RegulationSpain
-
Hadassah Medical OrganizationEnrolling by invitationCardiovascular Diseases | Lifestyle Risk ReductionIsrael
-
Zhan YuxinCompletedAnxiety | Emotional Regulation | MindfulnessChina
-
Centre Hospitalier Universitaire de BesanconINSERM UMR 1322 LINCRecruitingBinge-Eating Disorder | Healthy Volunteers | Emotional EatingFrance
-
CHU de ReimsRecruitingObesity | Binge-Eating DisorderFrance
-
Ludwig-Maximilians - University of MunichUniversity of Hamburg-Eppendorf; Introvision e.VCompleted
-
Alexandria UniversityBenha UniversityCompletedUndergraduate Health Professional StudentsEgypt
-
University of HoustonAmerican Cancer Society, Inc.; Herald Cancer AssociationCompletedBreast Cancer | Breast NeoplasmUnited States